FY2028 Earnings Estimate for Kamada Issued By Sidoti

Kamada Ltd. (NASDAQ:KMDA) – Analysts at Sidoti issued their FY2028 earnings per share estimates for shares of Kamada in a note issued to investors on Tuesday, August 18th. Sidoti analyst J. Sidoti forecasts that the biotechnology company will post earnings of $0.60 per share for the year. The consensus estimate for Kamada’s current full-year earnings is $0.49 per share.

KMDA has been the topic of several other reports. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. William Blair set a $15.00 price target on Kamada in a report on Tuesday, July 21st. Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Finally, Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kamada presently has a consensus rating of “Buy” and an average target price of $13.00.

Kamada Price Performance

Shares of NASDAQ:KMDA opened at $7.89 on Thursday. The company has a market cap of $453.75 million, a P/E ratio of 20.76, a P/E/G ratio of 0.64 and a beta of 0.86. The business has a fifty day simple moving average of $7.26 and a 200-day simple moving average of $7.94. Kamada has a 52 week low of $6.50 and a 52 week high of $9.35.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The company had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million.

Hedge Funds Weigh In On Kamada

Large investors have recently modified their holdings of the company. Marshall Wace LLP raised its holdings in shares of Kamada by 25.9% in the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 40,514 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Kamada by 43.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock worth $1,183,000 after purchasing an additional 50,608 shares during the period. Huntleigh Advisors Inc. increased its position in Kamada by 5.5% during the 4th quarter. Huntleigh Advisors Inc. now owns 149,374 shares of the biotechnology company’s stock worth $1,055,000 after purchasing an additional 7,812 shares in the last quarter. Two Sigma Investments LP increased its position in Kamada by 4.3% during the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock worth $761,000 after purchasing an additional 4,504 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Kamada in the first quarter valued at approximately $582,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th will be given a dividend of $0.17 per share. This represents a yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th. Kamada’s payout ratio is 50.00%.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.